2018 News Releases

2018 News Releases

CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal
06 Dec 2018

Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.

New Study Finds Significantly Greater Costs Associated with Multi-Vessel Disease in Medicare Patients Compared to those with Single Vessel Disease following an Acute Myocardial Infarction
08 Nov 2018

Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients

Science Center and Biotech Leader CSL Behring Partner to Accelerate Academic Research in the Search for New Medicines and Possible Cures
22 Oct 2018

Partnership to identify and help commercialize potential new medicines at research and academic institutions across the Greater Philadelphia region

CSL Behring to Feature Secondary Immunodeficiency Symposium at the 2018 Meeting of the European Society for Immunodeficiencies (ESID)
22 Oct 2018

ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency

CSL Donates to Indonesian Relief Operations
09 Oct 2018

CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.

CSL Named One of the Top Companies in the World for Diversity and Inclusion
18 Sep 2018

Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index

CSL Behring Delivers on its Promise to Support Alpha 1 Patients at the 28th Annual European Respiratory Society Congress
13 Sep 2018

• Hosts Patient-Focused Symposium on Alpha 1 Management
• Raises Money to Support Disease Awareness

IDELVION® 3500 IU Vials Now Available to Provide Convenience to Patients
23 Aug 2018

- The only treatment for hemophilia B FDA approved for up to 14-day dosing is now available in larger, 3500 IU vial size
- IDELVION is now offered in 5 convenient vial sizes to fit any dosing regimen: 250, 500, 1000, 2000 and 3500 IU
- New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients

CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
20 Jul 2018

• Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP

• CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients, and Privigen®, the No.1 intravenous immunoglobulin used in U.S. hospitals

CSL Behring, Leader in Rare Diseases, Hosts a Symposium on CIDP, Presents 7 Poster Sessions Featuring PATH Study Data at the 15th International Congress on Neuromuscular Diseases
05 Jul 2018

- CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment

- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients and Privigen®, approved for treating CIDP since 2013

A New Generation of Coagulation Specialists is Advancing Research with Support From CSL Behring Global Grant
22 Jun 2018

Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.

CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology
15 Jun 2018

- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients
- CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress

IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes
31 May 2018

• IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions
• New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients

Hemophilia Association of New Jersey Recognizes CSL CEO Paul Perreault as “Humanitarian Man of the Year”
14 May 2018

HANJ President David Lechner presented the award to Perreault at the association’s 38th Annual Testimonial Dinner Dance

Patient Advocacy Groups Focus on Key Issues Affecting Patients
26 Apr 2018

Five patient advocacy organizations are awarded LEAD Grants to support their advocacy initiatives in 2018

CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
20 Apr 2018

- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM

- Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms

- CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients and Privigen®, the No.1 intravenous immunoglobulin used in hospitals is now available for CIDP patients

Life-Saving Medicines Donated for Patients in the Developing World
12 Apr 2018

CSL Behring Marks World Hemophilia Day by Shipping IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia

Forbes Magazine Names CSL Limited Among Top 50 Employers in the World
20 Mar 2018

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth

FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
16 Mar 2018

First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP